This company listing is no longer active
TBGN.F Stock Overview
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Oxurion NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.17 |
| 52 Week High | €2.00 |
| 52 Week Low | €0.17 |
| Beta | 0.38 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -91.54% |
| 3 Year Change | -94.33% |
| 5 Year Change | -97.28% |
| Change since IPO | -98.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| TBGN.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -3.9% | -3.1% |
| 1Y | -91.5% | -1.8% | 20.9% |
Return vs Industry: TBGN.F underperformed the US Biotechs industry which returned -8.9% over the past year.
Return vs Market: TBGN.F underperformed the US Market which returned -20.7% over the past year.
Price Volatility
| TBGN.F volatility | |
|---|---|
| TBGN.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TBGN.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine TBGN.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 42 | Tom Graney | www.oxurion.com |
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME.
Oxurion NV Fundamentals Summary
| TBGN.F fundamental statistics | |
|---|---|
| Market cap | US$5.66m |
| Earnings (TTM) | -US$30.82m |
| Revenue (TTM) | US$1.19m |
4.7x
P/S Ratio-0.2x
P/E RatioIs TBGN.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TBGN.F income statement (TTM) | |
|---|---|
| Revenue | €1.13m |
| Cost of Revenue | €612.00k |
| Gross Profit | €516.00k |
| Other Expenses | €29.67m |
| Earnings | -€29.16m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Mar 24, 2023
| Earnings per share (EPS) | -0.094 |
| Gross Margin | 45.74% |
| Net Profit Margin | -2,584.93% |
| Debt/Equity Ratio | -1,068.1% |
How did TBGN.F perform over the long term?
See historical performance and comparison